These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
4. Disease registries and outcomes research in children: focus on lysosomal storage disorders. Jones S; James E; Prasad S Paediatr Drugs; 2011 Feb; 13(1):33-47. PubMed ID: 21162599 [TBL] [Abstract][Full Text] [Related]
5. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis. Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884 [TBL] [Abstract][Full Text] [Related]
6. Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America. Giugliani R J Inherit Metab Dis; 2012 Sep; 35(5):871-7. PubMed ID: 22231381 [TBL] [Abstract][Full Text] [Related]
7. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Seregin SS; Amalfitano A Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776 [TBL] [Abstract][Full Text] [Related]
8. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Hollak CE; Aerts JM; Aymé S; Manuel J Orphanet J Rare Dis; 2011 Apr; 6():16. PubMed ID: 21496291 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers for gene therapy clinical trials of lysosomal storage disorders. Rossi A; Malvagia S; la Marca G; Parenti G; Brunetti-Pierri N Mol Ther; 2024 Jun; ():. PubMed ID: 38850023 [TBL] [Abstract][Full Text] [Related]
10. Disease models for the development of therapies for lysosomal storage diseases. Xu M; Motabar O; Ferrer M; Marugan JJ; Zheng W; Ottinger EA Ann N Y Acad Sci; 2016 May; 1371(1):15-29. PubMed ID: 27144735 [TBL] [Abstract][Full Text] [Related]
11. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Schey C; Milanova T; Hutchings A Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518 [TBL] [Abstract][Full Text] [Related]
12. Update on treatment of lysosomal storage diseases. Bruni S; Loschi L; Incerti C; Gabrielli O; Coppa GV Acta Myol; 2007 Jul; 26(1):87-92. PubMed ID: 17915580 [TBL] [Abstract][Full Text] [Related]
13. Treatment perspectives for the lysosomal storage diseases. Grabowski GA Expert Opin Emerg Drugs; 2008 Mar; 13(1):197-211. PubMed ID: 18321157 [TBL] [Abstract][Full Text] [Related]
14. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. Haskins M ILAR J; 2009; 50(2):112-21. PubMed ID: 19293456 [TBL] [Abstract][Full Text] [Related]
16. Ten plus one challenges in diseases of the lysosomal system. Grabowski GA; Whitley C Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545 [TBL] [Abstract][Full Text] [Related]
17. An update on gene therapy for lysosomal storage disorders. Nagree MS; Scalia S; McKillop WM; Medin JA Expert Opin Biol Ther; 2019 Jul; 19(7):655-670. PubMed ID: 31056978 [TBL] [Abstract][Full Text] [Related]
18. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729 [TBL] [Abstract][Full Text] [Related]